Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Autonomix Medical, Inc. Common Stock (AMIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.5
1 Year Target Price $11.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.59M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 1.14 - 42.40 | Updated Date 06/30/2025 |
52 Weeks Range 1.14 - 42.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -75.39% | Return on Equity (TTM) -145.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5102236 | Price to Sales(TTM) - |
Enterprise Value -5102236 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2780480 | Shares Floating 2396412 |
Shares Outstanding 2780480 | Shares Floating 2396412 | ||
Percent Insiders 17.29 | Percent Institutions 15.47 |
Analyst Ratings
Rating 2 | Target Price 11.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Autonomix Medical, Inc. Common Stock
Company Overview
History and Background
Autonomix Medical, Inc. is a medical device company focused on developing innovative solutions for diagnosing and treating chronic diseases by targeting the autonomic nervous system. Founded with the aim of improving patient outcomes through precision diagnostics and targeted therapies.
Core Business Areas
- Medical Devices: Development and commercialization of medical devices that provide targeted access to the autonomic nervous system for diagnostic and therapeutic purposes.
- Neuromodulation: Exploring neuromodulation therapies to treat various chronic conditions by modulating autonomic nerve activity.
Leadership and Structure
The company is led by a team with expertise in medical device development, clinical research, and commercialization. Organizational structure includes departments focused on R&D, regulatory affairs, sales & marketing, and operations.
Top Products and Market Share
Key Offerings
- Autonomix System: A system that may provide targeted access to the autonomic nervous system. Market share data is currently limited due to the company's early stage of commercialization. Competitors are companies in the medical device and neuromodulation space focusing on autonomic nerve access.
Market Dynamics
Industry Overview
The medical device industry is competitive and innovative. The neuromodulation and autonomic nervous system targeting sectors are growing due to an increase in chronic diseases such as pain, gastrointestinal disorders and other conditions.
Positioning
Autonomix Medical, Inc. is positioned as an innovator in autonomic nervous system access and therapy. Competitive advantage may include their unique technology and targeted approach.
Total Addressable Market (TAM)
The total addressable market for neuromodulation and autonomic nervous system therapies is estimated to be in the billions of dollars. Autonomix Medical, Inc. is positioned to capture a portion of this TAM with its innovative technology.
Upturn SWOT Analysis
Strengths
- Innovative Technology
- Targeted Approach to Autonomic Nervous System
- Experienced Leadership Team
- Potential for Significant Market Growth
Weaknesses
- Limited Commercialization History
- Dependence on Regulatory Approvals
- Reliance on Funding
- Small Company Size
Opportunities
- Expanding into New Therapeutic Areas
- Partnering with Larger Medical Device Companies
- Securing Regulatory Approvals
- Increasing Awareness of Autonomic Nervous System Therapies
Threats
- Competition from Established Medical Device Companies
- Changes in Regulatory Requirements
- Technological Advancements by Competitors
- Market Adoption Challenges
Competitors and Market Share
Key Competitors
- MDGN
- BSX
- ABMD
Competitive Landscape
Autonomix Medical, Inc. competes with larger, established medical device companies. Its advantage lies in its innovative technology, while its disadvantage is its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to analyze due to the company's recent emergence.
Future Projections: Future growth projections are dependent on regulatory approvals, product commercialization, and market adoption. Analyst estimates may be available as the company grows.
Recent Initiatives: Recent initiatives may include clinical trials, regulatory submissions, and market development activities.
Summary
Autonomix Medical, Inc. is an emerging medical device company with innovative technology targeting the autonomic nervous system. It has the potential for significant growth in the neuromodulation space. Key challenges include competition from larger companies, regulatory hurdles, and securing adequate funding. The company's long-term success depends on its ability to successfully commercialize its products and gain market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Financial Disclosures (where available)
- Industry Reports
- Market Analysis
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autonomix Medical, Inc. Common Stock
Exchange NASDAQ | Headquaters The Woodlands, TX, United States | ||
IPO Launch date 2024-01-29 | President, CEO & Director Mr. Bradley Hauser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 8 | Website https://autonomix.com |
Full time employees 8 | Website https://autonomix.com | ||
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.